10 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:TNDM) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 8 | 0 | 0 |
| Last 30D | 0 | 0 | 2 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 4 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $25.1, with a high estimate of $35.00 and a low estimate of $20.00. Surpassing the previous average price target of $17.30, the current average has increased by 45.09%.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Travis Steed | B of A Securities | Raises | Neutral | $30.00 | $15.00 |
| Matt O'Brien | Piper Sandler | Raises | Neutral | $21.00 | $14.00 |
| Jonathan Block | Stifel | Raises | Hold | $20.00 | $16.00 |
| Lee Hambright | Bernstein | Raises | Market Perform | $25.00 | $18.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $24.00 | $17.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $35.00 | $24.00 |
| Anthony Petrone | Mizuho | Raises | Neutral | $21.00 | $18.00 |
| Jeff Johnson | Baird | Raises | Outperform | $30.00 | $18.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $22.00 | $16.00 |
| Patrick Wood | Morgan Stanley | Raises | Equal-Weight | $23.00 | $17.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tandem Diabetes Care compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Tandem Diabetes Care's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Tandem Diabetes Care's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Tandem Diabetes Care: A Financial Overview
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3M period, Tandem Diabetes Care showcased positive performance, achieving a revenue growth rate of 2.17% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tandem Diabetes Care's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -8.49% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Tandem Diabetes Care's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -15.9%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Tandem Diabetes Care's ROA stands out, surpassing industry averages. With an impressive ROA of -2.42%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 3.38, Tandem Diabetes Care faces challenges in effectively managing its debt levels, indicating potential financial strain.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.